Serina Therapeutics’ (SER) “Buy” Rating Reaffirmed at BTIG Research

Serina Therapeutics (NYSEAMERICAN:SER)‘s stock had its “buy” rating restated by investment analysts at BTIG Research in a research report issued to clients and investors on Monday, Benzinga reports. They presently have a $8.00 price target on the stock. BTIG Research‘s target price would suggest a potential upside of 367.84% from the company’s current price.

Serina Therapeutics Price Performance

Shares of NYSEAMERICAN SER traded up $0.06 during trading on Monday, reaching $1.71. The company had a trading volume of 38,290 shares, compared to its average volume of 1,431,775. Serina Therapeutics has a twelve month low of $1.22 and a twelve month high of $5.25. The stock has a market capitalization of $43.43 million, a PE ratio of -0.90 and a beta of 1.19. The stock has a 50-day moving average price of $2.24 and a two-hundred day moving average price of $2.08. The company has a current ratio of 6.65, a quick ratio of 6.65 and a debt-to-equity ratio of 0.16.

Serina Therapeutics (NYSEAMERICAN:SER) last released its quarterly earnings data on Thursday, August 13th. The company reported ($0.55) EPS for the quarter.

Serina Therapeutics Company Profile

Serina Therapeutics is a clinical-stage biopharmaceutical company developing medicines designed to provide longer-lasting and more consistent therapeutic effects. The company uses its proprietary POZ polymer technology to modify existing drug compounds, with the goal of extending their duration of action and potentially improving treatment convenience and tolerability.

Serina’s lead program is POZ-apomorphine, also referred to as SER-252, an investigational therapy being developed for patients with advanced Parkinson’s disease.